Biotest (BIO) AI Stock Analysis

• Market Cap: €1.40B
• Dividend Yield: 0.16%
• Average Volume (3M): 161.00
• Price to Earnings (P/E): 64.1
• Beta (1Y): -0.08
• Revenue Growth: -18.82%
• EPS Growth: -113.85%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 92
• 30 Day Avg. Volume: 161
• PEG Ratio: 1.07
• Price to Book (P/B): 4.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: €40.00 ▲(0.00%Upside)

Biotest's overall stock score is impacted primarily by its financial performance and technical analysis. While the balance sheet and cash flow improvements are positives, the technical indicators show bearish momentum, and the valuation is challenged by a negative P/E ratio. The lack of earnings call data and corporate events further limits a comprehensive assessment.

Biotest Business Overview & Revenue Model

Company Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

How the Company Makes Money

Biotest generates revenue through the manufacturing and sale of plasma protein products and biotherapeutic drugs. The company's key revenue streams include sales of immunoglobulins, which are essential for patients with immune deficiencies; clotting factors used for treating hemophilia and other bleeding disorders; and albumin solutions used in intensive care settings. Biotest also engages in research and development activities aimed at expanding its product portfolio and improving existing therapies. Strategic partnerships and collaborations with other pharmaceutical and biotechnology firms can also contribute to its earnings by facilitating market expansion and distribution of its products.

Biotest Financial Statement Overview

Summary

Biotest shows balanced financial performance with a stable balance sheet and improved cash flows. However, there are challenges in maintaining consistent profitability due to operational inefficiencies.

Income Statement

Biotest's income statement shows a mixed performance. Gross Profit Margin improved to 30.82% in the latest year, coupled with a positive Net Profit Margin of 3.63%, indicating moderate profitability. However, the company experienced a significant drop in Gross Profit from the previous year, suggesting volatility in profit generation. Revenue growth from 2023 to 2024 was 6.08%, which is positive but marked by a decline in EBIT and EBITDA margins, indicating rising operational costs or inefficiencies.

Balance Sheet

The balance sheet of Biotest indicates a stable financial position. The Debt-to-Equity Ratio stands at 1.13, reflecting a balanced capital structure. Return on Equity is modest at 4.97%, showing moderate returns to equity holders. The Equity Ratio of 37.00% suggests a strong equity base relative to total assets, enhancing financial stability. However, the increase in total debt over time could pose potential risks if not managed well.

Cash Flow

Biotest's cash flow statements reveal stable cash flow management. Operating Cash Flow to Net Income Ratio is 2.31, indicating strong cash generation relative to net income. Free Cash Flow improved significantly to a positive $32.2 million in 2024 from a negative position in the prior year, suggesting robust cash flow improvement. However, the fluctuation in free cash flow growth over the years denotes potential instability in cash generation capability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
726.20M	684.60M	516.10M	515.60M	484.20M
	Gross Profit
223.80M	280.30M	124.90M	80.70M	130.10M
	EBIT
94.50M	143.50M	-13.00M	-52.10M	-13.20M
	EBITDA
120.40M	179.00M	28.30M	-17.70M	16.00M
	Net Income Common Stockholders
26.40M	127.00M	-31.60M	-63.30M	-31.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
119.50M	118.50M	136.60M	117.50M	89.20M
	Total Assets
1.43B	1.41B	1.20B	1.10B	1.13B
	Total Debt
597.20M	689.80M	574.30M	496.30M	469.10M
	Net Debt
489.40M	581.70M	457.70M	391.90M	397.80M
	Total Liabilities
903.30M	912.00M	831.90M	723.80M	689.70M
	Stockholders Equity
530.70M	498.90M	371.10M	380.40M	441.60M
Cash Flow		Free Cash Flow
32.20M	-36.10M	-69.80M	15.70M	-43.70M
	Operating Cash Flow
60.90M	-2.70M	-40.50M	33.90M	-16.70M
	Investing Cash Flow
-25.70M	1.30M	-37.00M	-23.40M	-14.60M
	Financing Cash Flow
-35.40M	-6.80M	89.60M	22.60M	42.00M

Biotest Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 40.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Negative. The current price of 40 is below the 20-day moving average (MA) of 42.47, below the 50-day MA of 42.47, and below the 200-day MA of 41.68, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 21.26 is Positive, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BIO.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
BIO	50 Neutral	€1.40B	64.15	-4.72%	0.16%	-18.82%	-113.85%
0NZY		€1.38B	40.42	17.48%	3.05%	―	―
0QXH		€771.72K	―		―	―	―
0IRF		€1.27B	―	-20.51%	―	―	―
MEDOF		$354.31M	21.81	2.99%	―	―	―
FYB	63 Neutral	€504.32M	5.89	-26.06%	―	-10.32%	-250.76%